Virginia Cancer Patient “Living with (Stage 4) Cancer” Thanks to Clinical Trial

Dr. Alexander I. Spira presented promising research findings at The American Societyof Clinical Oncology (ASCO) to help those with lung cancer. (FAIRFAX, VIRGINIA) June 27, 2022 –– Chuck Tonkin, 82, has been battling cancer since 2018. Now with stage 4 lung cancer, with metastatic disease to his brain, has found a new drug, adagrasib, that is giving him his life …

 NEXT Oncology Gives Patient Her Life Back with Clinical Trials 

P53, guardian of the genome, prevents solid tumor growth (SAN ANTONIO) June 10, 2022 –– Lindalou Trevino was the first patient to enroll in clinical trial PC14586, and because of the success of this new drug, she has renewed hope and a new lease on life. PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the …

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center 

New trial clinical trial is focused on novel therapy for triple negative breast cancer. (SAN ANTONIO) April 14, 2022 –– When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 …

NEXT Oncology Adds Dr. Sharon Wilks to Phase I Clinical Investigation Team

Wilks to focus on advancements in novel therapies for breast cancer (SAN ANTONIO) December 8, 2021 –– Medical oncologist Dr. Sharon Wilks joins NEXT Oncology bringing more than 30 years of research and clinical experience to the practice. NEXT Oncology’s Phase I oncology centers provide patients with advanced cancer access to the newest treatments available. Dr. Wilks focuses on research …

NEXT Oncology Partners with Spanish Hospital System to Open Two Phase I Clinical Centers

 New venture marks third and fourth site expansion in five months  (SAN ANTONIO) November 18, 2021 –– NEXT Oncology, founded by internationally known cancer researcher Dr. Anthony Tolcher, has entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain. The venture increases global access to new agents and anticancer therapies for …

Next Oncology Logo

NEXT Oncology expands phase I program with VCS partnership

NEXT Oncology and Virginia Cancer Specialists have joined forces, launching NEXT Virginia, a cancer clinic, in September 2021. This partnership will also help expand VCS’s phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to the VCS Research Institute. The expanded phase I program will begin this fall, while the stand-alone …

Next Oncology Expands Phase I Program with Virginia Cancer Specialists Partnership

Joint venture brings access to proprietary Phase I program to more patients (SAN ANTONIO) October 5, 2021 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I and developmental therapeutics cancer research program and bring the latest …

Austin patients get more access to cancer trials with Next Oncology

Nicole Villalpando Austin American-Statesman – view article Lynne Xavier, 55, remembers when her husband was part of clinical trials for rectal cancer at MD Anderson in Houston.  “Watching him to go back and forth and back and forth and the wear on him,” she said, made the Austinite decide not to participate in any clinical trials out of town when she was …

SA cancer research group expanding to Austin, Europe

Next Oncology is advancing plans to expand its clinical trials facilities footprint nationally and internationally despite a global health crisis impacting that timeline. The San Antonio-based cancer research company has recently opened the first such facility outside of its headquarters home and already has other centers in various stages of development. “The next 12 months are going to be absolutely …